personalized weight loss plans glp-1 medications and affordable telehealth plan Dietitians boost GLP-1 therapy success

Kim JW, Ko SH, Cho JH, Sun C, Hong OK, Lee SH, et al

There are no hydroquinones in this formulation, so there is little chance of irritation in this sensitive area

PLoS One 11, e0157298

Semaglutide is part of a medication group known as GLP-1 receptor agonists

Semaglutide Wegovy / Ozempic Mechanism: GLP-1 receptor agonist (single target) Weight loss: ~15-17% body weight (STEP trials, 68 weeks) Dosing: Weekly injection, titrated from 0.25mg to 2.4mg Common side effects: Nausea, vomiting, diarrhea, constipation (typically transient) Availability: Longer track record, more widely available Cardiovascular data: SELECT trial demonstrated 20% reduction in major cardiovascular events Tirzepatide Zepbound / Mounjaro Mechanism: Dual GLP-1 + GIP receptor agonist (two targets) Weight loss: ~20-22% body weight (SURMOUNT trials, 72 weeks) Dosing: Weekly injection, titrated from 2.5mg to 15mg Common side effects: Similar GI profile to semaglutide

Further research would be required in this field